  Towards a definition of intractable headache for use in clinical practice and trials; Schoenen, Jean  ; et alin Cephalalgia : An International Journal of Headache (2006), 26(9), 1168-1170 Detailed reference viewed: 15 (2 ULg)Ergotamine in the acute treatment of migraine: a review and European consensus.; ; et al in Brain : A Journal of Neurology (2000), 123 ( Pt 1) Ergotamine has been used in clinical practice for the acute treatment of migraine for over 50 years, but there has been little agreement on its place in clinical practice. An expert group from Europe ... [more ▼] Ergotamine has been used in clinical practice for the acute treatment of migraine for over 50 years, but there has been little agreement on its place in clinical practice. An expert group from Europe reviewed the pre-clinical and clinical data on ergotamine as it relates to the treatment of migraine. From this review, specific suggestions for the patient groups and appropriate use of ergotamine have been agreed. In essence, ergotamine, from a medical perspective, is the drug of choice in a limited number of migraine sufferers who have infrequent or long duration headaches and are likely to comply with dosing restrictions. For most migraine sufferers requiring a specific anti-migraine treatment, a triptan is generally a better option from both an efficacy and side-effect perspective. [less ▲] Detailed reference viewed: 19 (2 ULg)Repeatability of the Intensity Dependence of Cortical Auditory Evoked Potentials in the Assessment of Cortical Information Processing; ; et al in Cephalalgia : An International Journal of Headache (1999), 19(10), 873-9 Data on repeatability and optimal settings are needed when studying the influence of drugs on the intensity dependence of auditory evoked cortical potentials (IDAP). IDAP was recorded at intervals of 1, 2 ... [more ▼] Data on repeatability and optimal settings are needed when studying the influence of drugs on the intensity dependence of auditory evoked cortical potentials (IDAP). IDAP was recorded at intervals of 1, 2, and 24 h at two centers in 22 healthy volunteers. Settings were modified to compare fixed versus randomly varied stimulus repetition rate, as well as 30 Hz and 100 Hz low pass filters. Repeatability was assessed for different intervals and different settings. Group means did not differ between centers, the 2-h or 24-h retest, or when using different settings. We observed an order effect for the 1 h retest. Fixed repetition rate and the 30 Hz filter improved repeatability with still high intraindividual variability. IDAP group means can be compared between centers for retest intervals of 2 h and 24 h and different settings. Variability is too large to compare individuals. [less ▲] Detailed reference viewed: 9 (0 ULg)Auditory evoked potentials in the assessment of central nervous system effects of antimigraine drugs.; ; et al in Cephalalgia : An International Journal of Headache (1999), 19(10), 880-5 Because the "intensity dependence" of cortical auditory evoked potentials (IDAP) is under serotonergic control, it can be used to assess central antimigraine effects of 5HT1B/1D agonists. We measured IDAP ... [more ▼] Because the "intensity dependence" of cortical auditory evoked potentials (IDAP) is under serotonergic control, it can be used to assess central antimigraine effects of 5HT1B/1D agonists. We measured IDAP before and 2 h after naratriptan (5 mg, n = 19) and zolmitriptan (5 mg, n = 19) in healthy volunteers. IDAP was expressed as the amplitude-stimulus intensity function ("ASF slope"). Naratriptan tended to increase ASF slope (mean difference 0.23 +/- 0.62 microV/10 dB, p = 0.06) while zolmitriptan (0.08 +/- 0.95 microV/10 dB, p = 0.35) did not. We assessed the suitability of IDAP for measuring central antimigraine drug effects using repeatability data (see companion paper). We calculated the trade-off between the size of the expected drug effects (ASF slope difference) and the necessary sample size. Because of poor repeatability 36 to 80 subjects are required to detect ASF slope changes in the 0.25-0.5 microV/10 dB range. These data can be used to design trials using IDAP. [less ▲] Detailed reference viewed: 15 (0 ULg) |
||
